Eli Lilly announces trial results of new weight loss, diabetes pill; stock booms
The Indianapolis-headquartered pharmaceutical company, known for selling weight loss drugs Mounjaro and Zepbound, published its findings for the pill called orforglipron in a news release on April 17.
"We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year," said David A. Ricks, Lilly's chair and CEO.
According to Ricks, orforglipron is a once-daily pill that, if approved, could be "readily manufactured and launched at scale for use by people around the world."
Lilly's shares had increased roughly 16% by 1 p.m. ET after the results of the trial were released.
Lilly said its new pill would continue the company's "mission to reduce chronic diseases like type 2 diabetes," which it says is expected to roughly impact 760 million adults by 2050.
During the trial, the pill lowered patients' A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, according to Lilly. The company also said that more than 65% of patients taking the highest dose of orforglipron reached an A1C less than or equal to 6.5%, which is below the American Diabetes Association's (ADA) defined threshold for diabetes.
For people without diabetes, a normal A1C is below 5.7%, the Cleveland Clinic says. Between 5.7% and 6.4% is considered prediabetes, it added.
Patients taking the highest dose of Lilly's new pill lost an average of 16 pounds during the trial, according to the company. Participants' weight loss had not yet plateaued by the time the trial ended, which could indicate further weight reduction was possible, Lilly said.
It is unclear when Lilly's new pill will be made available to the public, as more trials will be conducted and it faces approval by the Food and Drug Administration (FDA).
Ricks said this is only the first of seven Phase 3 studies "examining the safety and efficacy of orforglipron across people with diabetes and obesity."
So far, Lilly said the adverse effects of its new pill are consistent with GLP-1s, a class of medications primarily used to treat type 2 diabetes.
The most commonly reported side effects were "gastrointestinal-related and generally mild to moderate in severity," Lilly said. The trial found that different doses (3 mg, 12 mg and 36 mg) caused varying chances of side effects, which included diarrhea (19%, 21% and 26%), nausea (13%, 18% and 16%), dyspepsia (10%, 20% and 15%), constipation (8%, 17% and 14%) and vomiting (5%, 7% and 14%).
"With some concern of elevated rates of nausea and vomiting heading into today's readout, these result firmly validate the tolerable profile of orforglipron," BMO Capital Markets analyst Evan Seigerman said, per Reuters.
Additionally, no liver-related safety signal was observed in the trial, Lilly said.
Lilly's new pill can be taken at any time of the day without restrictions on food and water intake, according to the company.
Contributing: Reuters
This article originally appeared on USA TODAY: Lilly shows findings of new weight loss drug orforglipron; stock booms
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Eli Lilly raising GLP-1 prices abroad raises more questions about US pricing: BofA analyst
Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing in peer developed nations. The effort, known as Most Favored Nations pricing, has been a goal of Trump's since his first term. He has doubled down on the efforts this year, giving pharma companies 60 days to implement changes in pricing in what he deems "freeloading" nations. The US drug economy differs from European and other developed nations, which rely on the government to negotiate prices with drugmakers, resulting in lower prices globally. "While we agree that the costs for breakthrough medicines should be more fairly shared across developed countries, we must also address the underlying structural issues in the US that have contributed to high drug prices. The US system is complex and opaque," Lilly said in a statement Thursday. The stock was up 1% in trading Friday. Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America Securities research analyst Tim Anderson questioned who would actually be impacted by the raised prices. "LLY has announced it will raise GLP-1 pricing in the UK by a healthy margin (a doubling of price, but it's unclear to whom this higher price realistically applies). It expects to do something similar in other European countries (but worth appreciating: in most European markets, there aren't price agreements in place between GLP-1 manufacturers and governments, meaning these are out-of-pocket spending markets)," Anderson wrote. Ultimately, whether or not the move results in lower US prices remains a question, though Anderson believes it likely will not. "Does this mean it will actually cut the price on the GLP-1s in the US (and on other medicines)? To us, the answer is quite likely no, or at least, not in a way that creates P&L [profit and loss planning ] risk," he wrote. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
a day ago
- Bloomberg
Novo Nordisk's Wegovy Gets US Approval for Liver Disease
Novo Nordisk A/S 's blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market for the increasingly prevalent condition. The shot was cleared for the disease known as MASH, or metabolic-associated steatohepatitis, in adults with moderate to advanced scar tissue in the liver.
Buzz Feed
a day ago
- Buzz Feed
People Share Frustrating Parts Of Today's Beauty Standards
As women in the modern world, it's hard enough dealing with everyday pressures. But on top of that, there's the added stress of having to look a certain way — especially with social media broadcasting idealized versions of faces and bodies. Are people allowed to have fine lines and wrinkles anymore? Be in public without a stitch of makeup? Do we all need to have a perfectly slim waist, but curves in all the other right places? Have rock-hard abs and less than 20% body fat? It's a cycle of trying to find peace, then logging into social media and seeing everyone looking perfect. Ladies, it's time to share your opinon: What are the most frustrating parts of today's beauty standards? Is it the pressure to get Botox and fillers? To fall into a certain weight range with medications like GLP-1s on the rise? Will you share your frustrations with us? Share your thoughts in the comments. For those who prefer to stay anonymous, you can fill out the anonymous form below. Your response may be featured in an upcoming BuzzFeed post.
